Prof. Dario Vignali, Ph.D.
Chair and Distinguished Professor at the University of Pittsburgh School of Medicine and Associate Director for Scientific Strategy at the UPMC Hillman Cancer Center. Prof. Vignali is a co-founding scientist of several companies including Potenza Therapeutics, which developed an NRP1-specific antibody and was acquired by Astellas in 2018.
